Home / Treatments / Gammagard
Gammagard denials: what the review data shows
Independent reviewers have decided 37 published cases where an insurer denied Gammagard — and they overturned the insurer 54.1% of the time. A denial for Gammagard is a starting position, not a final answer.
Published decisions
37
2001–2026
Overturned
54.1%
20 denials reversed
Conditions behind gammagard denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Small Fiber Polyneuropathy | 3 | 33.3% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 31 | 54.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 6 | 50% |
Typical time to a decision
5 days
Most land between 3 and 12 days
Handled as urgent
78.4%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Gammagard intravenous immune globulin infusions (35 grams infused every four weeks for six months). Hypogammaglobulinemia may occur in persons with systemic lupus erythematosus (SLE) and is a potential risk factor for infection. Researchers note that SLE patients have an intrinsically dysfunctional immune system which is exacerbated by disease activity and leaves them vulnerable to infection. Management of hypogammaglobulinemia in persons with SLE should be individualized and tailored to a patient’s individual risk of infection.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Gammagard intravenous immunoglobulin infusions (35 grams daily for three days, then 52 grams for one to two days every three to four weeks for one year). Finnerup and colleagues report that inadequate response to drug treatments constitutes a substantial unmet need in patients with neuropathic pain. Liu and colleagues explain that small fiber polyneuropathy may have various underlying causes, including associations with systemic autoimmune conditions, and that intravenous immunoglobulin is a first-line treatment for immune-mediated neuropathies such as Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Gammagard infusions 60 grams every four weeks. This patient’s records document small fiber neuropathy, which the provider noted is likely due to Sjogren’s. The provider has recommended treatment with Gammagard infusions. There is a lack of prospective randomized controlled clinical studies demonstrating the long-term safety and efficacy of intravenous immunoglobulin (IVIG) for the treatment of patients with small fiber neuropathy. Gaillet and colleagues reported data suggesting that IVIG treatment can be effective and well-tolerated in patients with small fiber neuropathy. However, the authors concluded that their findings “have to be confirmed in a randomized double-blinded placebo-controlled trial.” IVIG has been approved by the U.S.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Gammagard 75 grams, every four weeks x 11 refills. Autoimmune encephalitis is an often rapidly progressive inflammatory neurological disease with subacute onset. A diagnosis of autoimmune encephalitis is supported by the presence of subacute onset, altered mental status, or psychiatric symptoms, as well as new focal central nervous system, seizures not explained by a known seizure disorder, cerebrospinal fluid (CSF) pleocytosis, or magnetic resonance imaging (MRI) features suggestive of encephalitis. In addition, the patient should be evaluated for other diseases that can mimic autoimmune encephalitis and cause rapidly progressive encephalopathy.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Gammagardwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.